A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Insulin degludec (Primary) ; LY 3209590 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 16 Oct 2019 Planned End Date changed from 30 Dec 2019 to 7 Feb 2020.
- 16 Oct 2019 Planned primary completion date changed from 30 Dec 2019 to 7 Feb 2020.
- 03 Sep 2019 Status changed from recruiting to active, no longer recruiting.